Data published by the National Multiple Sclerosis Society show that Biogen, along with rival companies such as Teva Pharmaceutical Industries and Novartis Pharmaceuticals, haven't been shy about raising the list prices of these medicines. "Biogen Treads Tricky Path Between Politicians, Investors," at 10:43 a.m. EDT, in the third paragraph incorrectly included Roche Pharmaceuticals among the companies that have raised the list prices of their multiple sclerosis medicines.

(END) Dow Jones Newswires

August 18, 2017 19:04 ET (23:04 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Biogen Charts.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Biogen Charts.